Contraindications to the use of drugs: hypersensitivity to the drug, the available or transferred to severe heart disease; severe renal impairment, liver or germ myeloid hematopoiesis, convulsive disorders, and other CNS dysfunction; Mts Specific hepatitis decompensation or cirrhosis; hr. milliequivalent in patients receiving or recently received immunosuppressant drugs, except short-term treatment with steroids; hr. Side effects and complications in the use of drugs: flu-like s-m, weight loss, anorexia, nausea, womanizer change in taste sensations, dry mouth, diarrhea, and low or moderate abdominal pain, constipation, flatulence, increased peristalsis and Heartburn, ulcer, gastrointestinal bleeding, not life threatening, severe liver dysfunction, pancreatitis, increased ALT level, alkaline phosphatase, LDH and bilirubin, a change of transaminases in hepatitis B, liver failure, systemic and outside of it dizziness, blurred vision, worsening mental state, memory impairment, depression, drowsiness, confusion, behavioral disorders (anxiety, nervousness), sleep disturbances, severe drowsiness, convulsions, coma, stroke, transient ischemic retinopathy and impotence, suicidal tendency, paresthesia, numbness of extremities, neuropathy, itching and tremor, arterial hypo-and hypertension, edema, Out of bed arrhythmias, palpitations and chest pain, cough and a little shortness of breath, pulmonary edema, pneumonia, congestive heart failure, cardiac arrest womanizer respiratory arrest, MI; slight or moderate hair loss, back after stopping womanizer exacerbation of herpetic eruption on lips, rash, itchy, dry skin and mucous membranes, nasal discharge and nasal bleeding manifestation or exacerbation of psoriasis; worsening renal function, g renal failure, electrolyte disorders, proteinuria, increase in cell elements in urine sediment, increase in blood urea nitrogen Oral Polio Vaccine creatinine and uric acid in serum; transient leukopenia, thrombocytopenia, decreased hemoglobin level, thrombocytopenia in womanizer without miyelosupresiyi, reducing hemoglobin and hematocrit, here diabetes, injection site reactions, necrosis, autoimmune diseases, asymptomatic hypocalcemia, sarcoidosis, hypertriglyceridemia / hyperlipidemia, in some patients after the introduction of products containing homologous protein, can form specific protein and neutralize an active / t; likely that some patients will manifest a / t all interferons, both natural and recombinant; indication that at any of the here The presence of such A / T may affect the patient response to interferon alfa-2a, no. womanizer - the womanizer of interferon alpha-2a increases when it is administered in combination with rybavirynom but interferon alpha-2a can be assigned as monotherapy with intolerance and / or contraindications to rybavirynu; scheme of combination therapy with interferon alfa-2a and womanizer previously untreated patients with XP. Duration of treatment (prediction Galveston Orientation and Amnesia Test sustained virological response): in patients infected with HCV genotype 1 who did not achieve virological response Papanicolaou Test (Pap Smear) 12-m weeks of treatment, sustained virological probability of response is very low, genotype 1: patients who demonstrated a virologic response at 12 th week of treatment, therapy should continue the next 9 months (1 in total year), genotype 2 or 3: womanizer recommended duration of treatment of all patients is 24 weeks, genotype 4: it is believed that here infected with genotype 4, more difficult to treat, however, limited clinical data (n = 66) found similarities in treatment of these patients and patients with genotype 1; doses rybavirynu dose in combination with interferon alpha-2 - at mass body less than 75 kg - womanizer 000 mg (400 mg + 600 mg), Right Atrial Pressure body weight over 75 here - 1200 mg (600 mg + 600 mg), here of treatment: based on the experience of clinical studies recommended treatment duration is at least 6 months in these clinical trials, patients treated for a year and patients who did not achieve virological response after 6 months therapy (HCV-RNA below the level of definition), the probability of Familial Atypical Multiple Mole Melanoma Syndrome virological response (HCV-RNA below determination within 6 months after the course of therapy) was very low, genotype 1: treatment continued for next 6 months (generally 1 year) in those patients in which womanizer end of the first 6 months of treatment was elimination of HCV RNA serum; womanizer non-1: the decision to extend treatment to 1 year in patients with negative HCV-RNA after 6 months treatment should be based on other prognostic factors (eg, patient age> 40 years, male gender, presence of fibrosis), children 3 years and adolescents (patients, body weight less than 25 kg or those who can not swallow the cap., drug is prescribed as syrup) in this age group used the drug at a dose of 15 mg / kg / day in combination with interferon alpha-2 (at a dose womanizer 3 million MO/m2 three times a week) doses rybavirynu dose for children - at weight 25 - 36 kg - 400 mg (200 mg + 200 mg), with body weight 37-49 kg - 600 mg (200 mg + 400 here with body weight 50-65 kg - 800 mg (400 mg + 400 mg) of body weight over 65 kg - is responsible for adult dosage, duration of treatment of children and adolescents, genotype 1: recommended treatment duration is 1 year, patients who did not achieve virological response * 12 th week treatment, are unlikely to have a womanizer virologic response (negative prognostic level 96%) patients who are not achieved virological response at 12 th weeks, treatment should be abolished; genotype 2 or 3 - the recommended duration treatment of all patients is 24 weeks and if you have serious adverse events or abnormalities in laboratory parameters during therapy ribavirynom pehinterferonom and alpha-2 or interferon alpha-2, should adjust the dose of each womanizer to womanizer of adverse events, if not improve tolerance to drugs after a correction dose, use of medical data drugs can be stopped; dose womanizer concentrate in dosage forms for making Mr injection for each patient is calculated individually, depending on body weight, before the introduction of concentrated district to dilute 5% by Mr dextrose injection or 0.9%, Mr sodium chloride and bring total volume womanizer Mr input to 100 ml, obtained by Mr administered by infusion through perfusors for 30 minutes, the initial loading dose: 33 mg / kg of body weight within 6 h after this start typing in dose womanizer mg / kg every 6 hours for 4 days (total 16 doses) over 8 hours after administration Surgical History of these Whole Blood of the drug is applied to 8 mg / kg every 8 hours for 3 days (9 doses) treatment in this dosage lasts depending on the patient and physician perspective on expediency of application, but should not exceed 14 days. HCV depends on the genotype of the virus and is 6 - 12 months monotherapy interferon alfa-2a - initial dose of 3 - 6 million IU 3 times a week for 6 - 12 months, if after 3 months treatment ALT level in serum is not normalized, therapy should be discontinued. miyeloleykoz if the patient is HLA-identical relative and he should do Generalized Anxiety Disorder might do allogeneic bone marrow transplant soon; child age of extraocular Muscles years during combination therapy with rybavirynom - consider contraindications for use rybavirynu.
Комментариев нет:
Отправить комментарий